ARG CEO Paul Bishop just received the following feedback from a Global Pharmaceutical Sponsor: “LPLV occurred on Friday. Congrats to […]
Why did you choose to pursue this MS? Shay: “My goal was to verify my industry knowledge through formal studies. […]
Challenge: A pivotal Phase III clinical trial of C1 inhibitor for the prophylactic treatment of hereditary angioedema managed by ARG […]
The ARG SAB (Strategic Advisory Board) regularly convenes to discuss emerging trends and issues in rare diseases, adding to the […]
ARG’s primary goal is to improve and prolong the lives of the people affected by rare diseases through the clinical trials we manage. We realize our patient-centric approach by carefully cultivating relationships, fostering meaningful communication, and anticipating and addressing all of the challenges in our studies.